Abstract:ABSTRACT The current treatments for toxoplasmosis are only active against fast-growing tachyzoites, present in acute infections, with little effect on slow-growing bradyzoites within tissue cysts, present in latent chronic infections. The mitochondrion of Toxoplasma gondii is essential for its survival, and one of the major anti-parasitic drugs, atovaquone, inhibits the mitochondrial electron transport chain at the coenzyme Q:cytochrome c oxidoreductase site. Coenzyme Q (also known as ubiquinone [UQ]) consists of a quinone head and a lipophilic, isoprenoid tail that anchors UQ to membranes. The synthesis of the isoprenoid unit is essential for cell growth and is inhibited by lipophilic bisphosphonates, which inhibit the parasite growth. In this work, we investigated the effect of lipophilic bisphosphonates on the chronic stages of T. gondii . We discovered that three lipophilic bisphosphonates (BPH-1218, BPH-1236, and BPH-1238), effective for the acute infection, were also effective in controlling the development of chronic stages. We showed effectiveness by testing them against in vitro cysts and in vivo derived tissue cysts and, most importantly, these compounds reduced the cyst burden in the brains of chronically infected mice. We monitored the activity of infected mice non-invasively and continuously with a novel device termed the CageDot. A decrease in activity accompanied the acute phase, but mice recovered to normal activity and showed signs of hyperactivity when the chronic infection was established. Moreover, treatment with atovaquone or BPH-1218 ameliorated the hyperactivity observed during the chronic infection. IMPORTANCE Treatment for toxoplasmosis is challenged by a lack of effective drugs to eradicate the chronic stages. Most of the drugs currently used are poorly distributed to the central nervous system, and they trigger allergic reactions in a large number of patients. There is a compelling need for safe and effective treatments for toxoplasmosis. Bisphosphonates (BPs) are analogs of inorganic pyrophosphate and are used for the treatment of bone disorders. BPs target the isoprenoid pathway and are effective against several experimental parasitic infections. Some lipophilic BPs can specifically inhibit the mitochondrial activity of Toxoplasma gondii by interfering with the mechanism by which ubiquinone is inserted into the inner mitochondrial membrane. In this work, we present the effect of three lipophilic BPs against T. gondii chronic stages. We also present a new strategy for the monitoring of animal activity during disease and treatment that is non-invasive and continuous.

Evaluation of the Effects of Sulfamethoxazole onToxoplasma gondiiLoads and Stage Conversion in IFN-γ Knockout Mice Using QC-PCR

Evaluation of the effects of sulfamethoxazole on Toxoplasma gondii loads and stage conversion in IFN-gamma knockout mice using QC-PCR.

An animal model for establishing chemotherapy against intractable toxoplasmosis in immunocompromised hosts by the use of ifn-γ knockout mice

Effect of Changqing Capsule on Toxoplasma Gondii Tachyzoites As Demonstrated by Ultrastructual Studies

Evaluation of a Real-Time PCR Assay Based on the Single-Copy SAG1 Gene for the Detection of Toxoplasma Gondii.

Evaluation of Potential Anti-Toxoplasmosis Efficiency of Combined Traditional Herbs in a Mouse Model

Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase

Cytotoxic and Immunomodulatory Activity of Curcumin and Chitosan on Experimental Toxoplasmosis

Evaluation of In Vitro Cytotoxic and Apoptotic Effects of Miltefo-sine on the Toxoplasma gondii RH Strain

Treatment of mice with S4B6 IL-2 complex prevents lethal toxoplasmosis via IL-12- and IL-18-dependent interferon-gamma production by non-CD4 immune cells

Peroral Infectivity of Toxoplasma Gondii in Bile and Feces of Interferon-Gamma Knockout Mice.

Lipophilic bisphosphonates reduced cyst burden and ameliorated hyperactivity of mice chronically infected with Toxoplasma gondii

Metabolomic Profiling of Mice Serum During Toxoplasmosis Progression Using Liquid Chromatography-Mass Spectrometry

Could Metformin Modulate the Outcome of Chronic Murine Toxoplasmosis?

The Detection of Toxoplasma Gondii ME49 Infections in BALB/c Mice Using Various Techniques.

In Vitro Effect of Combined Traditional Chinese Medicine (changqing Capsule) on the Tachyzoites of Toxoplasma Gondii

Anti-parasitic activity of a chimeric peptide Cecropin A (2-8)-Melittin (6-9) (CM11) against tachyzoites of Toxoplasma gondii and the BALB/c mouse model of acute toxoplasmosis

Effects of different drugs and hormone treatment on Toxoplasma gondii glutathione S-transferase 2

Ifn-Gamma-Regulated Toxoplasma Gondii Distribution and Load in the Murine Eye

Spiramycin-loaded maltodextrin nanoparticles as a promising treatment of toxoplasmosis on murine model

Antiparasitic Effects of Niosomal Formulations of Curcumin and Silymarin Against Toxoplasma gondii In Vitro